New Three-Drug attack on tough cancers shows promise
NCT ID NCT03449901
Summary
This study tested whether adding a new drug called ADI-PEG20 to two standard chemotherapy drugs (gemcitabine and docetaxel) could better control advanced cancers that had stopped responding to initial treatments. It enrolled 98 adults and some adolescents with specific advanced soft tissue sarcomas, bone cancers, or small cell lung cancer. The goal was to see if this three-drug combination could slow cancer growth and extend life more effectively than the standard two-drug chemo alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT-TISSUE SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Sarcoma Oncology Center
Santa Monica, California, 90403, United States
-
Stanford Medicine
Palo Alto, California, 94304, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.